Omeros has been granted a patent for a method to prevent angiogenesis in mammals with angiogenesis-dependent diseases. The method involves administering a MASP-2 inhibitory agent, such as a MASP-2 antibody, to inhibit the process. Claim 1 specifically focuses on treating benign tumors using a MASP-2 inhibitory monoclonal antibody. GlobalData’s report on Omeros gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Omeros, Peptide pharmacophores was a key innovation area identified from patents. Omeros's grant share as of May 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Treating benign tumors by inhibiting angiogenesis with masp-2 antibody
A recently granted patent (Publication Number: US11981748B2) discloses a method for treating angiogenesis-dependent benign tumors in mammalian subjects. The method involves administering a MASP-2 inhibitory agent, specifically a MASP-2 inhibitory monoclonal antibody or its fragment, to inhibit angiogenesis. The monoclonal antibody or fragment includes specific heavy and light chain variable regions as defined by SEQ ID NO:67 and SEQ ID NO:69.
Furthermore, the patent claims cover the administration of the composition through various routes such as subcutaneous, intraperitoneal, intramuscular, intra-arterial, intravenous, or as an inhalant. This method aims to effectively inhibit angiogenesis in benign tumors like hemangiomas, acoustic neuromas, neurofibromas, trachomas, carcinoid tumors, and pyogenic granulomas in mammalian subjects. The specificity of the MASP-2 inhibitory agent and the defined administration routes highlight the innovative approach proposed in this patent for treating angiogenesis-dependent benign tumors.
To know more about GlobalData’s detailed insights on Omeros, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
